Sparrow Pharmaceuticals
Sparrow Pharmaceuticals is a targeted cardiometabolic therapeutics company delivering improved outcomes for millions of patients who struggle to control their disease with current options for diabetes and related metabolic conditions. The Company’s lead candidate, clofutriben, is a first-in-class, once-daily, oral HSD-1 inhibitor initially in development for type 2 diabetes with elevated cortisol. HSD-1 inhibition targets an underlying etiology of treatment resistance across the spectrum of metabolic dysfunction and is complementary to leading antidiabetic agents. Sparrow is led by an experienced team of biotech executives, endocrinologists, and drug development veterans with a shared commitment to precision medicine in metabolic disease.www.sparrowpharma.com
1
MENTIONS
1
EPISODES
1
PODCASTS
Search complete. 1 mention across 1 episode found for "Sparrow Pharmaceuticals".
Sep 16, 2026
Otis JohnsonHOST
The preclinical CRO market is projected to grow from ten point one one billion dollars in twenty twenty-five to thirty-two point six one billion by twenty thirty-four, driven by rising trial complexity and outsourcing now representing over forty-nine percent of total R&D spending globally.
Otis JohnsonHOST
In a new Q&A from our sister publication, Pharm Exec, Dr. Elena Christofides, scientific advisor for Sparrow Pharmaceuticals, discussed how cortisol dysregulation mechanistically reduces GLP-1 effectiveness by disrupting glucose signaling, insulin signaling, and fuel partitioning.
Otis JohnsonHOST
When patients fail to achieve expected GLP-1 response, screening for cortisol dysfunction becomes critical.
Otis JohnsonHOST
Yet, many providers still default to non-adherence assumptions rather than diagnosing underlying pathology that may be limiting medication effectiveness.